

**Reference:** FOI.ICB-2425/128

**Subject:** ADHD Services Right to Choose

*I can confirm that the ICB does hold some of the information requested; please see responses below:*

| QUESTION  | RESPONSE   |                             |  |   |   |   |          |              |                             |                                  |                                  |          |         |         |  |  |                   |         |            |          |   |                    |         |      |  |  |                |        |      |  |  |               |         |            |            |            |
|---|--|-----------------------------|--|---|---|---|----------|--------------|-----------------------------|----------------------------------|----------------------------------|----------|---------|---------|--|--|-------------------|---------|------------|----------|---|--------------------|---------|------|--|--|----------------|--------|------|--|--|---------------|---------|------------|------------|------------|
| <p>I would like to request how much is spent on Right to Choose services for patients being assessed and treated for ADHD.</p> <p>As well as overall figures, I would like to request specific costs for each assessment, diagnosis, and any management carried out by the Right to Choose provider.</p> <p>This should include the prescription of any medications, in particular, those in the amphetamine class, and the physical health monitoring of these medications.</p> <p><i>Clarification received: for adults please.</i></p> <p><i>I only need the information for what the current payments are to Right to Choose providers for the ADHD services they provide. I do not Need historical data.</i></p> | <p>Please read the information below the table, which explains the conditions applied to the calculation of the figures in each column.</p> <table><tr><th>A</th><th>B</th><th>C</th><th>D</th><th>E</th></tr><tr><th>Provider</th><th>Invoice date</th><th>Total spend related to ADHD</th><th>Costs related to ADHD assessment</th><th>Costs related to ADHD medication</th></tr><tr><td>ADHD 360</td><td>22.7.24</td><td>£10,100</td><td colspan="2">BNSSG ICB does not hold information which would enable further breakdown of costs.</td></tr><tr><td>Clinical Partners</td><td>30.6.24</td><td>£10,634.11</td><td>£6895.00</td><td>£3739.11<br/><br/>Of this, £2,419.11 is listed as prescription and medication costs</td></tr><tr><td>Jajawi &amp; Asker Ltd</td><td>22.7.24</td><td>£182</td><td colspan="2">Unable to disclose – please see notes below for Column A</td></tr><tr><td>Problem Shared</td><td>9.7.24</td><td>£950</td><td colspan="2">Unable to disclose – please see notes below for Column A</td></tr><tr><td>Psychiatry UK</td><td>16.7.24</td><td>£36,446.78</td><td>£17,142.84</td><td>£19,303.94</td></tr></table> | A                           | B  | C   | D | E | Provider | Invoice date | Total spend related to ADHD | Costs related to ADHD assessment | Costs related to ADHD medication | ADHD 360 | 22.7.24 | £10,100 | BNSSG ICB does not hold information which would enable further breakdown of costs. |  | Clinical Partners | 30.6.24 | £10,634.11 | £6895.00 | £3739.11<br><br>Of this, £2,419.11 is listed as prescription and medication costs | Jajawi & Asker Ltd | 22.7.24 | £182 | Unable to disclose – please see notes below for Column A |  | Problem Shared | 9.7.24 | £950 | Unable to disclose – please see notes below for Column A |  | Psychiatry UK | 16.7.24 | £36,446.78 | £17,142.84 | £19,303.94 |
| A   | B  | C                           | D  | E   |   |   |          |              |                             |                                  |                                  |          |         |         |  |  |                   |         |            |          |   |                    |         |      |  |  |                |        |      |  |  |               |         |            |            |            |
| Provider  | Invoice date   | Total spend related to ADHD | Costs related to ADHD assessment   | Costs related to ADHD medication  |   |   |          |              |                             |                                  |                                  |          |         |         |  |  |                   |         |            |          |   |                    |         |      |  |  |                |        |      |  |  |               |         |            |            |            |
| ADHD 360  | 22.7.24  | £10,100                     | BNSSG ICB does not hold information which would enable further breakdown of costs. |   |   |   |          |              |                             |                                  |                                  |          |         |         |  |  |                   |         |            |          |   |                    |         |      |  |  |                |        |      |  |  |               |         |            |            |            |
| Clinical Partners   | 30.6.24  | £10,634.11                  | £6895.00   | £3739.11<br><br>Of this, £2,419.11 is listed as prescription and medication costs |   |   |          |              |                             |                                  |                                  |          |         |         |  |  |                   |         |            |          |   |                    |         |      |  |  |                |        |      |  |  |               |         |            |            |            |
| Jajawi & Asker Ltd  | 22.7.24  | £182                        | Unable to disclose – please see notes below for Column A                           |   |   |   |          |              |                             |                                  |                                  |          |         |         |  |  |                   |         |            |          |   |                    |         |      |  |  |                |        |      |  |  |               |         |            |            |            |
| Problem Shared  | 9.7.24   | £950                        | Unable to disclose – please see notes below for Column A                           |   |   |   |          |              |                             |                                  |                                  |          |         |         |  |  |                   |         |            |          |   |                    |         |      |  |  |                |        |      |  |  |               |         |            |            |            |
| Psychiatry UK   | 16.7.24  | £36,446.78                  | £17,142.84   | £19,303.94  |   |   |          |              |                             |                                  |                                  |          |         |         |  |  |                   |         |            |          |   |                    |         |      |  |  |                |        |      |  |  |               |         |            |            |            |

|  |   |        |          |  |
|--|---|--------|----------|--|
|  |   |        |          | Of this,<br>£13,710.57 is<br>listed as<br>prescription and<br>medication costs |
|  | <b>The Private<br/>Pharmacy<br/>group<br/>(medication<br/>only)</b> | 8.4.24 | £2564.71 | N/A<br>£2564.71  |

**Explanatory notes:**

**Column A – Providers:**

- **ADHD 360** – the total spend in column C may include spend on Children’s ADHD as the lower age limit for referrals under Right to Choose is under 18 years of age and invoices are not separated according to age or type of contact (assessment, medication etc).
- **Clinical Partners** have been an assessment only service for some time, however, medication and prescription costs continue to be charged to BNSSG ICB for those patients who began medication before this part of the service was withdrawn for Right to Choose referrals.
- **Jajawi & Asker** – it is not possible to provide any further breakdown of costs outside of those stated in column C. Under Right to Choose rules, providers are required to invoice for activity in line with the prices in the NHS Standard Contract they hold with the ICB directly commissioning them (often referred to as the “Host Commissioner”). BNSSG ICB do not directly commission Jajawi & Asker and therefore, provision of further invoice details, including a breakdown of costs would risk disclosure of information not held by BNSSG ICB.
- **Problem Shared** – it is not possible to provide any further breakdown of costs outside of those stated in column C. Under Right to Choose rules, providers are required to invoice for activity in line with the prices in the NHS Standard Contract

they hold with the ICB directly commissioning them (often referred to as the “Host Commissioner”). BNSSG ICB do not directly commission Problem Shared and therefore, provision of further invoice details, including a breakdown of costs would risk disclosure of information not held by BNSSG ICB.

**Column B – Invoice date:**

- In order to provide current information, the figures in the table are taken from the latest invoices dated up to and including 22<sup>nd</sup> July 2024, to be received from each provider.
- Costs vary across all providers, as does the frequency with which they submit invoices, for example, some may submit an invoice on a regular basis such as weekly or monthly and others invoice on a more ad hoc basis.
- On occasion, BNSSG ICB is invoiced for activity which backing data later shows to be the responsibility of another ICB and in this instance, a credit note is requested from the provider to recover the charges levelled in error. As these are the latest invoices, backing data may not be available at this time so it is possible that the spend on these may reduce at a later date if any activity is found to not be the responsibility of BNSSG ICB.

**Column C – Total spend related to ADHD:**

Some providers offer both ADHD and Autism assessment services and consolidate costs for both within the same invoice. Where this has been the case, all reasonable steps have been taken to separate Autism spend from ADHD spend and only invoice lines which specifically mention “ADHD” or any medication related interventions have been included. This is because medication is only available from the listed Right to Choose providers following diagnosis of ADHD.

**Column D – Costs related to ADHD assessment:**

- This includes the costs of assessments as well as follow up appointments and charges where individuals Did Not Attend (DNA) their appointment. Costs for diagnosis would be included within the assessment fee.

|  |   |
|--|---|
|  | <ul style="list-style-type: none"> <li>• We are unable to provide costs per assessment as to do so would risk disclosure of information that is not held by BNSSG ICB.</li> </ul> <p><b>Column E – Costs related to ADHD medication:</b></p> <ul style="list-style-type: none"> <li>• This includes titration appointments, physical health monitoring, medication costs, prescription fees and end of treatment reviews.</li> <li>• Where prescription and medication costs have been specifically referenced on the invoice, these have also been included and are part of the total cost in this column, not separate.</li> <li>• It is not possible to break these down any further into charges for amphetamine class medications as invoices do not include this level of detail.</li> <li>• Please note that medication costs will not be listed for patients who have been discharged to their GP under shared care, if this includes the prescription and supply of medication.</li> </ul> |
|--|---|

***The information provided in this response is accurate as of 25 July 2024 and has been approved for release by Sarah Truelove, Deputy Chief Executive and Chief Finance Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***